Our program is ideally suited to participate in the clinical trial activities of the Eastern Cooperative Oncology Group. The University of Rochester Cancer Center (URCC) is a health and research institute organized as a multihospital consortium involving l tertiary care center and 4 full-service community hospitals. It is committed to clinical and basic laboratory research, patient care, and education. The faculty hold primary academic appointments in the Center as well as a teaching appointment in a University clinical or basic science department. It serves a population of 1.2 million people. Our ECOG membership has grown to include 5 additional performance sites involving outreach community hospitals (4 located in the regional Northeast section of the country and l satellite member in Quebec, Canada. Continued long-term goals and specific aims supported by this ECOG application include: l) participation of multimodal Phase II and III clinical studies; 2) accelerate the advances of cancer therapy in adult patients through increased accrual; 3) enhance basic- science clinical interactions; 4) further develop cancer control and prevention initiatives; 5) provide wide dissemination of information through rapid data collection and publications; 6) maintenance of quality and timely data management and 7) continued service to the administrative responsibilities of the Group. The transfer of multidisciplinary technology in the daily cancer practice setting benefits not only the those patients entered onto research protocols, but also to cancer patients treated with """"""""standard"""""""" approaches. Through ECOG communication, education, and optimal treatment, we can hopefully provide state-of-the-art care, increased survival and improved quality of life to our cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011083-30
Application #
2414061
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1999-04-30
Budget Start
1997-05-01
Budget End
1998-04-30
Support Year
30
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769

Showing the most recent 10 out of 222 publications